B1448 is intended to treat Acute Pulmonary Embolism and its mechanism of action is the same as that of PUK for treating STEMI.
(1) The new generation of fibrin-specific thrombolytic drug, with a unique mechanism of thrombolysis, low risk of systemic bleeding, and great safety;
(2) Low rate of re-thrombosis after thrombolysis;
(3) Advanced manufacturing process, and affordable to the patients; PUK has been covered in the National Reimbursed Drug List (NRDL) three times in a row.
B1448 Phase II clinical trial was completed.